CN115916187A - 治疗蛋白病相关的游荡的方法 - Google Patents

治疗蛋白病相关的游荡的方法 Download PDF

Info

Publication number
CN115916187A
CN115916187A CN202180036165.2A CN202180036165A CN115916187A CN 115916187 A CN115916187 A CN 115916187A CN 202180036165 A CN202180036165 A CN 202180036165A CN 115916187 A CN115916187 A CN 115916187A
Authority
CN
China
Prior art keywords
dementia
wandering
patient
disease
fasudil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180036165.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·麦卡利斯特
S·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ursa Pharmaceutical Co
Original Assignee
Ursa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ursa Pharmaceutical Co filed Critical Ursa Pharmaceutical Co
Publication of CN115916187A publication Critical patent/CN115916187A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180036165.2A 2020-03-25 2021-01-08 治疗蛋白病相关的游荡的方法 Pending CN115916187A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062994527P 2020-03-25 2020-03-25
US62/994,527 2020-03-25
US202063005913P 2020-04-06 2020-04-06
US63/005,913 2020-04-06
PCT/US2021/012587 WO2021194608A1 (en) 2020-03-25 2021-01-08 Methods of treating proteinopathy- associated wandering

Publications (1)

Publication Number Publication Date
CN115916187A true CN115916187A (zh) 2023-04-04

Family

ID=77855102

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180036165.2A Pending CN115916187A (zh) 2020-03-25 2021-01-08 治疗蛋白病相关的游荡的方法

Country Status (7)

Country Link
US (2) US11642352B2 (https=)
EP (1) EP4125879A4 (https=)
JP (1) JP2023518707A (https=)
CN (1) CN115916187A (https=)
CA (1) CA3170073A1 (https=)
MX (1) MX2022011518A (https=)
WO (1) WO2021194608A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
WO2021216139A1 (en) 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
MX2023000600A (es) * 2020-07-14 2023-02-13 Woolsey Pharmaceuticals Inc Metodos de tratamiento de proteinopatias.
CN118251226A (zh) * 2021-11-12 2024-06-25 悟而喜制药公司 治疗肌萎缩性侧索硬化症的方法以及其给药方案
US20240423998A1 (en) 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
EP4479035A4 (en) * 2022-02-17 2026-02-25 Woolsey Pharmaceuticals Inc FASUDIL TASTE MASKING ORAL FORMULATIONS
CN118922193A (zh) * 2022-02-17 2024-11-08 悟而喜制药公司 具有离子交换树脂的法舒地尔口服制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3464012B2 (ja) 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
CN100444843C (zh) * 1998-08-10 2008-12-24 旭化成制药株式会社 法舒地尔盐酸盐缓释口服制剂
WO2005117896A1 (de) 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
WO2008036459A2 (en) * 2006-07-20 2008-03-27 Borchardt Allen J Inhibitors of rho kinase
WO2008019395A2 (en) 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
EP2285217A4 (en) 2008-05-12 2011-06-08 Amnestix Inc CONNECTIONS TO IMPROVE LEARNING AND MEMORY
CN101612157A (zh) 2008-06-26 2009-12-30 天津红日药业股份有限公司 法舒地尔诱导成年脑内源性神经干细胞再生的用途
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases
US9980972B2 (en) 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
WO2017195224A1 (en) 2016-05-09 2017-11-16 Istituto Superiore Di Sanita' Rho gtpase activating bacterial toxins for use in the treatment of disorders of the central nervous system by mucosal administration
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
MX2023000600A (es) * 2020-07-14 2023-02-13 Woolsey Pharmaceuticals Inc Metodos de tratamiento de proteinopatias.

Also Published As

Publication number Publication date
EP4125879A4 (en) 2024-04-03
US11642352B2 (en) 2023-05-09
CA3170073A1 (en) 2021-09-30
MX2022011518A (es) 2022-10-07
WO2021194608A1 (en) 2021-09-30
EP4125879A1 (en) 2023-02-08
US20210299140A1 (en) 2021-09-30
US20230226073A1 (en) 2023-07-20
JP2023518707A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
CN115916187A (zh) 治疗蛋白病相关的游荡的方法
US11666583B2 (en) Methods of treating cortical dementia associated wandering
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
JP2023530120A (ja) 血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法
US11311553B1 (en) Methods of treating 4-repeat tauopathies
CA3184122A1 (en) Methods of treating proteinopathies
JP2026032031A (ja) グリコシダーゼインヒビターを含む医薬
CN109563089B (zh) 促进app正常加工的化合物
EP4125910A1 (en) Methods of using rho kinase inhibitors to treat frontotemporal dementia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination